海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients with Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and are Treated with Insulin (ODYSSEY DM - Insulin)
- Hypercholesterolemia MedDRA version: 18.1 Level: LLT Classification code 10020604 Term: Hypercholesterolemia System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Austria, Finland, France, Germany, Greece, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States
- 2015-10-01
Authorised
- A study to compare an investigational ultra-rapid insulin, LY900014 with another mealtime insulin, Fiasp when both are used along with a long-acting insulin in people with type 1 diabetes
- Diabetes Mellitus, Type 1 MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Austria, Canada, Czech Republic, Germany, Romania, Spain, United Kingdom, United States
- 2018-11-23
Authorised
- Exercise and blood glucose levels in patients with type I Diabetes
- Type 1 diabetes;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Austria
- 2014-01-08
Authorised
- Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease - Zevalin® first line in Follicular lymphoma
- Patients with follicular lymphoma grade I-IIIa and stage III–IV (as well as for selected patients with extended abdominal stage II). MedDRA version: 8.1 Level: LLT Classification code 10052314 Term: Lymphatic disorder
- Austria, Germany, Sweden
- 2007-01-05
Authorised
- A double-blind, placebo-controlled, three arm randomised multi-centre Gynaecologic Cancer InterGroup trial of AZD2171, in combination with platinum-based chemotherapy and as a single agent maintenance therapy, in women with ovarian cancer relapsing more than 6 months following completion of first line platinum-based treatment. - ICON6 GCIC Trial (International Collaborative Ovarian Neoplasm 6)
- epitehlial ovarian carcinoma, fallopian tube carcinoma, primary serous peritoneal carcinoma relapsing more than 6 months after completion of first-line platinum based chemotherapy br>MedDRA version: 14.1 Level: LLT Classification code 10033131 Term: Ovarian carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: LLT Classification code 10052171 Term: Peritoneal carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Australia, Canada, New Zealand, Spain, United Kingdom
- 2007-05-16
Authorised
- International, randomized, open-label, Phase 3 trial of gemcitabine/cisplatin plus PF-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung cancer
- First line treatment of chemotherapy-naive patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV) Non Small Cell Lung Cancer (NSCLC)
- Austria, Belgium, Czech Republic, Germany, Hungary, Italy, Portugal, Slovakia, Spain, United Kingdom
- 2005-11-23
Authorised
- A Randomised, Open-Label Preliminary Study To Assess The Effects Of Etanercept 50 mg Once Weekly For 24 Weeks And Etanercept 50 mg Twice Weekly For 12 weeks Reducing To Etanercept 50 mg Once Weekly For 12 weeks On Nail And Skin Symptoms In Patients With Nail Psoriasis And Plaque Psoriasis.
- Nail psoriasis
- Austria, France, Greece, Italy, United Kingdom
- 2007-04-06
Authorised
- Characterization of Renin-Angiotensin-System at patients with Empagliflozin therapy and Angiotensin-converting enzyme inhibition.
- Chronic kidney disease with and without type 2 diabetes MedDRA version: 20.0 Level: LLT Classification code 10076411 Term: Chronic kidney disease stage 4 System Organ Class: 100000004857 MedDRA version: 20.0 Level: LLT Classification code 10076410 Term: Chronic kidney disease stage 3 System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Austria
- 2016-10-11
Authorised
- A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic Acid
- Primary biliary cirrhosis br>MedDRA version: 20.0 Level: SOC Classification code 10019805 Term: Hepatobiliary disorders System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Australia, Austria, Belgium, Canada, Germany, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom, United States
- 2012-02-13
Authorised
- Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis - -
- Chronic hepatitis C infection MedDRA version: 12.1 Level: LLT Classification code 10019752 Term: Hepatitis C virus (HCV)
- Austria, Czech Republic, Germany, Greece, Hungary, Italy, Spain
- 2011-02-10